BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and AstraZeneca (NYSE:AZN) are among those companies with late stage drugs in trials that specifically target genetic mutations. Both BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s BMN-673, which is in phase 3 trials, and Astra’s Olaparib, which may get the EU’s go-ahead in ovarian cancer this year, address a mutation of the BRCA 1 and BRCA 2 gene that is often associated with breast … Continue reading Biotech Losers: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Novavax, Inc. (NASDAQ:NVAX), Biogen Idec Inc (NASDAQ:BIIB)